טוען...
Isolated Abducens Nerve Palsy Following Pembrolizumab
Pembrolizumab is a checkpoint inhibitor targeting the programmed cell death 1 receptor of lymphocytes and is used in the treatment of solid tumours including melanoma. The authors report a 64-year-old man treated with pembrolizumab for stage IV cutaneous melanoma (primary cutaneous melanoma of the r...
שמור ב:
| הוצא לאור ב: | Neuroophthalmology |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7202430/ https://ncbi.nlm.nih.gov/pubmed/32395170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/01658107.2019.1566385 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|